Casgevy Outlook: Morgan Stanley’s Take on CRISPR Therapeutics
Morgan Stanley upgraded CRISPR Therapeutics to Equal Weight, $60 target (~21% upside), sees Casgevy growth but mixed valuation views.
/ 5 items
#CRSP↓
CRISPR Therapeutics Jumps on Takeover Buzz
CRISPR Therapeutics stock surges 6% amid fresh speculation that Vertex Pharmaceuticals may pursue an acquisition.
CRISPR Therapeutics Stock Rises on Takeover Rumors
CRISPR Therapeutics shares climbed after rumors suggested a large U.S. biopharma company may be exploring a potential acquisition, fueled by progress in gene editing programs and growing Casgevy sales.
FDA’s New Fast-Track Plan for Custom Gene Editing Could Transform Rare Disease Treatments
The FDA is unveiling a faster approval pathway for custom gene-editing therapies, aiming to spark major investment and accelerate cures for rare diseases through Crispr-based innovations.
Intellia Pauses Gene Therapy Trials After Patient Develops Severe Liver Injury
Intellia Therapeutics halts MAGNITUDE trials of nex-z gene therapy after patient hospitalization with Grade 4 liver toxicity. Over 650 patients enrolled in ATTR amyloidosis studies.